

1 **Title: Estimating the potential impact and diagnostic requirements for SARS-CoV-2**
2 **test-and-treat programs**

3
4 **Authors:** Alvin X. Han¹, Emma Hannay², Sergio Carmona², Bill Rodriguez², Brooke E.
5 Nichols^{1,2,3,†}, Colin A. Russell^{1,3,†}

6
7 **Affiliations:**

8 ¹Department of Medical Microbiology & Infection Prevention, Amsterdam University
9 Medical Center, University of Amsterdam, Amsterdam, The Netherlands

10 ²Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

11 ³Department of Global Health, School of Public Health, Boston University, Boston, MA,
12 USA

13 †Contributed equally

14
15 **Correspondence:** Alvin X. Han (x.han@amsterdamumc.nl) and Colin A. Russell
16 (c.a.russell@amsterdamumc.nl)

17

18 **Abstract (201/200 words):**

19 Oral antivirals have the potential to reduce the public health burden of COVID-19. However,
20 now that we have exited the emergency phase of the COVID-19 pandemic, declining SARS-
21 CoV-2 clinical testing rates (average testing rates = $\ll 10$ tests/100,000 people/day in low-
22 and-middle income countries; < 100 tests/100,000 people/day in high-income countries;
23 September 2023) make the development of effective test-and-treat programs challenging. We
24 used an agent-based model to investigate how testing rates and strategies affect the use and
25 effectiveness of oral antiviral test-to-treat programs in four country archetypes of different
26 income levels and demographics. We find that in the post-emergency phase of the pandemic,
27 in countries where low testing rates are driven by limited testing capacity, significant
28 population-level impact of test-and-treat programs can only be achieved by both increasing
29 testing rates and prioritizing individuals with greater risk of severe disease. However, for all
30 countries, significant reductions in severe cases with antivirals are only possible if testing
31 rates were substantially increased with high willingness of people to seek testing. Comparing
32 the potential population-level reductions in severe disease outcomes of test-to-treat programs
33 and vaccination shows that test-and-treat strategies are likely substantially more resource
34 intensive requiring very high levels of testing ($\gg 100$ tests/100,000 people/day) and antiviral
35 use suggesting that vaccination should be a higher priority.

36

37 **Main Text**

38 **Introduction**

39 Antiviral therapies such as anti-SARS-CoV-2 monoclonal antibodies, replication inhibitors,
40 protease inhibitors, and host-directed therapies can be used to treat COVID-19, reducing the
41 probability of severe disease to varying degrees.¹ Direct-acting antiviral drugs, such as
42 molnupiravir² and nirmatrelvir–ritonavir (Paxlovid),³ have the potential to substantially lower
43 disease burden given their efficacy and convenience of oral dosing. Nirmatrelvir–ritonavir, in
44 particular, can reduce incidence of adverse events in high-risk individuals (i.e. ≥ 60 years of
45 age (over-60y) or an adult ≥ 18 years with a relevant comorbidity) by 46-89%.^{3,4} Given their
46 ability to lower viral load,³ these drugs could also potentially be used to control SARS-CoV-2
47 transmission.⁵ To achieve maximum impact, these drugs must typically be administered
48 within a few days of symptom onset. Given limited resources and the relatively high cost of
49 these drugs,⁶ along with the need to administer drugs quickly after symptom onset,^{2,3}
50 diagnostic testing remains an essential first step for identifying suitable drug recipients.

51

52 Oral antivirals (the term “*antivirals*” refers only to oral direct antivirals for the rest of this
53 article) have the potential to reduce the disease burden of COVID-19 outbreaks. Various
54 studies have estimated $\sim 10\% - 40\%$ reduction in severe disease outcomes if antivirals were
55 distributed to $20\% - 50\%$ of all symptomatic infected individuals.^{5,7,8} However, none of these
56 studies have accounted for the diagnostic capacity required to identify and treat these cases
57 with antivirals. There have been substantial gaps in COVID-19 testing equity across country
58 income groups throughout the pandemic. Between January 2020 and March 2022, LMICs
59 were only testing at an average of 27 tests/100,000 people/day (tests/100K/day) as compared
60 to >800 tests/100K/day in high-income countries (HICs).⁹ In the post-public health
61 emergency phase of the pandemic, testing rates have dwindled down to less than 10

62 tests/100K/day and 100 tests/100K/day on average for LMICs and HICs respectively (as of
63 September 2023).⁹ Low testing rates severely underestimate COVID-19 cases,¹⁰ which not
64 only complicate antiviral demand forecasts but also create additional barriers to the effective
65 distribution and use of antivirals.

66
67 Here, we used an agent-based model (PATAT)^{11,12} to demonstrate how testing rates and
68 strategies affect the use and impact of antivirals. In the model, we focused on antigen rapid
69 diagnostic tests (Ag-RDTs) which can easily be performed at point-of-care or be used as self-
70 tests with short turnaround time needed to quickly identify high-risk infected individuals.¹³
71 We computed the potential impact of test-and-treat programs on infections, severe cases, and
72 deaths averted in three LMIC archetypes with distinct demographic structures – Brazil,
73 Georgia, and Zambia – and the Netherlands as an HIC example, all under varying levels of
74 vaccination coverage. The LMIC archetypes were selected as the age demography of their
75 populations were largely representative of the 132 other LMICs as classified by the World
76 Bank (Figure 1).^{14,15} Our findings highlight the limits and expected outcomes of COVID-19
77 oral antiviral treatment programs under realistic testing and vaccination landscapes.

78

79 **Results**

80 *Dynamic epidemic simulations with PATAT*

81 We first provide key details of the PATAT model and assumptions to contextualize our
82 results. See Methods and Supplementary Information for full description of the model and
83 parameters. We simulated SARS-CoV-2 epidemics in each country under a range of average
84 effective reproduction number (i.e. $R_e = 0.9$, 1.2 (doubling time = 6-9 days), 1.5 (doubling
85 time = 3-5 days), and 2.0 (doubling time = 1-3 days)) during the first week of each
86 simulation. These doubling times coincide the range reported for prominent Omicron

87 subvariants as well, including BA.2 (~3 days)¹⁶, BA.5 (5-6 days)¹⁷ and XBB.1.5 (9-10
88 days)¹⁸ (Figure S1). All simulations were initialized with 1% of the population infected at the
89 start of the epidemic. We did not model varying levels of population immunity due to the
90 lack of comprehensive country-specific infection data and complexities in parameterizing the
91 proportion and protection conferred to individuals with infections by different variant
92 infection histories in the past. Instead, the different R_e values should be viewed as the
93 collective outcome of population immunity from previous infections, intrinsic
94 transmissibility of the variant virus as well as effects of any existing any public health
95 interventions other than vaccination and oral antivirals. For each R_e value and country, we
96 performed two sets of simulations – one with and the other without the distribution of
97 antivirals. For each set of simulations, we assumed three vaccination coverage: 10%, 50%
98 and 90%. We randomly assigned vaccination status across the simulated population but
99 assumed that vaccination was age-tiered such that the older individuals were vaccinated first.
100 For comparability between countries and as a simplification, we assumed that protection rates
101 against infection and severe disease were 29% and 70% respectively, which were based on
102 the more conservative, lower average estimates of vaccine effectiveness against BA.1 across
103 different vaccines (i.e. mRNA and ChAdOx1 nCoV-19 vaccine) and doses (i.e. 1-3 doses).^{19–}
104 ²¹
105
106 The relative susceptibility of individuals to infection,^{22,23} probability of becoming
107 symptomatic,^{24,25} probability of developing severe disease,^{24,25} and the probability of death
108 ^{26,27} depend on the age of the individual (Table S1). We assumed that only high-risk
109 individuals (i.e. ≥ 60 years of age (over-60y) or an adult ≥ 18 years with a relevant
110 comorbidity) who tested positive at clinics (e.g. a self-reported self-test would be insufficient
111 to access antivirals) would receive a course of antivirals. We also randomly assigned 20% of

112 the population to have a 40% increase in relative risk to developing severe disease because of
113 pre-existing comorbidities (e.g. obesity, diabetes, people living with HIV, etc.).^{28,29} As a
114 simplification, we assumed that the prevalence of comorbidities was independent of age.
115 Although the phase 2/3 trial of nirmatrelvir–ritonavir reported 89% relative risk reduction
116 among unvaccinated high-risk patients infected by the Delta variant-of-concern,³ we assumed
117 that an antiviral course conferred a 46% risk reduction for infected high-risk individuals to
118 severe disease outcomes based on a separate cohort study on the effectiveness of
119 nirmatrelvir–ritonavir among high-risk patients infected by Omicron BA.1 independent of
120 their vaccination status.⁴

121

122 *Impact of test-and-treat*

123 We simulated the implementation of test-and-treat programs during SARS-CoV-2 epidemic
124 waves in three different LMICs (Brazil, Georgia, and Zambia) with distinct population
125 demography (Figure 1) and the Netherlands under different levels of vaccine coverage (10%,
126 50% or 90%) and average test availability (10, 100 or 500 tests/100K/day). We assumed that
127 tests were only available at health clinics and that 65% of individuals with mild symptoms
128 would likely seek testing at clinics based on surveys of testing behaviour during the
129 pandemic.^{30,31} Test-seeking individuals would, however, only be tested if tests were
130 available. From our simulations, we found that the likelihood of detecting an infection ranged
131 between 0.06% and 64.6%, depending on the country simulated, epidemic intensity,
132 vaccination coverage and test availability (Figure S2). Generally, detection is more likely
133 with a larger proportion of over-60y individuals (i.e. the more likely cases will be
134 symptomatic and seek testing), lower reproduction rate R_e , higher vaccination coverage and
135 greater test availability (i.e. any of the aforementioned factors directly or indirectly increases
136 the surplus of tests available for symptomatic individuals).

137

138 At 10 tests/100K/day, test-and-treat programs are unlikely to have any population-level
139 impact on disease transmission in all countries (Figure S3). At higher testing rates (≥ 100
140 tests/100K/day) and lower R_e (≤ 1.5), there were modest differences between simulated
141 countries. We found that antivirals largely only have a limited impact on total infections
142 averted (Figure S3), in large part because 58-67% of all transmission events were attributed
143 to asymptomatic and pre-symptomatic individuals (Figure S4A). However, in Georgia and
144 the Netherlands where $>30\%$ of the population are over-60y and high-risk individuals
145 transmitted almost half of all infections (Figure S4B), increasing testing rates to 100 (500)
146 tests/100K/day, accompanied by uncapped distribution of antivirals, could reduce total
147 infections by $\sim 12\%$ ($\sim 22\text{-}24\%$). On the other hand, regardless of testing rates, infections
148 averted were $<12\%$ and $<4\%$ in Brazil and Zambia respectively, both of which have smaller
149 over-60y populations (i.e. Brazil: 15%; Zambia: 6% of population; Figure S3A) and where
150 most infections are transmitted by low-risk individuals (Figure S4B). Across all settings and
151 testing rates, increasing vaccination coverage did not change the proportion of infections
152 averted by antivirals substantially.

153

154 If testing rates increased to 500 tests/100K/day, the proportion of severe cases averted due to
155 antivirals would depend on the proportion of over-60y in the population, with Zambia, Brazil,
156 Georgia and the Netherlands, maximally reducing up to an average of 46%, 55%, 67% and
157 68% of severe cases respectively through test-and-treat strategies (Figure 2). Linking
158 antiviral treatment to testing programs at a rate of 10 tests/100K/day did not generate any
159 impact under any scenario, including when 90% of the population were vaccinated. Raising
160 testing rates to 100 tests/100K/day – a widely publicized global target during the pandemic –
161 and treating all high-risk, test-positive patients with antivirals substantially increased the

162 proportion of severe cases averted at lower R_e (i.e. proportion of severe cases averted at $R_e =$
163 0.9 (1.2) with 10-90% vaccination coverage: Zambia, 17-20% (3-4%); Brazil, 24-55% (6-
164 14%); Georgia, 50-65% (13-30%) and the Netherlands, 48-67 (12-31%); Figure 2). The
165 impact was greatest in Georgia and the Netherlands given their substantial >60y population.
166 As R_e increases (≥ 1.5), the likely population demand for tests also increased, and
167 correspondingly >100 tests/100K/day was needed to ensure that high-risk individuals could
168 be identified to initiate treatment (i.e. proportion of severe cases averted at $R_e = 1.5$ (2.0)
169 with 10-90% vaccination coverage at 100 tests/100K/day: Zambia, 2-4% (0-3%); Brazil, 1-
170 4% (0-1%); Georgia, 3-9% (1-2%); Netherlands, 3-10% (0-2%). At 500 tests/100K/day:
171 Zambia, 9-16% (7-9%); Brazil, 11-36% (6-9%); Georgia, 24-66% (8-14%); Netherlands, 28-
172 65% (6-18%); Figure 2). Although we did not model the impact of antivirals in reducing the
173 likelihood of death, developing severe disease precedes dying from COVID-19 in our model
174 (see Methods), the number of deaths averted thus follow similar trends as severe cases
175 averted (Figure S5).

176
177 At testing rates of ≤ 10 tests/100,000 people/day, use of antivirals made negligible
178 contributions to reducing severe disease at all levels of vaccine coverage. At testing rates
179 ≥ 100 tests/100,000/people/day, higher vaccination coverage was associated with a smaller
180 absolute number of severe cases averted by antivirals. However, at higher testing rates, the
181 proportion of severe cases averted by antivirals relative to no distribution of antivirals is
182 larger at higher vaccination coverage. This is because as infections decrease with higher
183 vaccination coverage, a greater percentage of severe cases could also be detected and treated
184 by antivirals assuming that the quantity of test availability is a constraining factor and that
185 demand in low vaccination scenarios would exceed supply.

186

187 *Distribution of test and antivirals to high-risk household contacts of test-positive individuals*

188 As antivirals must be administered quickly after symptom onset, one way to promptly
189 identify and treat infected high-risk individuals is to secondarily distribute self-tests to high-
190 risk household contacts who were exposed to the test-positive individuals. This would,
191 however, also result in a faster depletion of available test stocks under limited test
192 availability. We repeated our simulations with high-risk household contacts receiving Ag-
193 RDTs from clinics to perform self-test over the ensuing three days, initiating antiviral
194 treatment upon a positive diagnosis. In this scenario, however, there was little reduction in
195 total infections due to antivirals (Figure S6). In fact, when R_e was low (≤ 1.2) and at 100
196 tests/100K/day, distributing tests to high-risk household contacts for self-tests diverted away
197 test stocks that would otherwise be used to diagnose test-seeking symptomatic individuals
198 (which would, in turn, change their behavior to reduce transmission if tested positive). At 100
199 tests/100K/day across all R_e values, or at 500 tests/100K/day and higher R_e , the proportion of
200 severe cases and in turn, deaths averted diminished substantially by a factor of two- to ten-
201 fold (Figure S7-8) relative to no secondary distribution of Ag-RDTs to high-risk household
202 contacts (Figure 2 and Figure S5). Unless testing rates were increased to ≥ 500
203 tests/100K/day, 100 tests/100K/day remains inadequate to meet the testing demand of both
204 symptomatic individuals and high-risk household contacts to derive greater impact from test-
205 and-treat.

206

207 *Restricting symptomatic testing to high-risk individuals*

208 Given the modest impact of antivirals in reducing transmissions, testing could be targeted to
209 high-risk individuals only in order to distribute antivirals to as many infected high-risk
210 individuals as possible. This strategy can be effective in reducing severe cases and deaths by
211 test-and-treat when Ag-RDT availability is inadequate to test all symptomatic individuals

212 who seek testing, which was a common scenario in LMICs during the pandemic. Otherwise,
213 if most individuals only isolate themselves after a positive test, the testing restriction would
214 lead to excess tests available that are not effectively used to alter the behaviour of low-risk
215 infected individuals that curb onward transmissions.

216

217 In our model, restricting testing to high-risk groups when there are ample amount of tests to
218 diagnose non-high-risk symptomatic individuals as well resulted in more transmissions
219 (Figure S9) and severe cases (Figure 3). We estimated that there can be up to 56% more
220 infections at $R_e \leq 1.5$ if test availability was 500 tests/100K/day but were restricted to high-
221 risk individuals only. In Georgia, for example, restricting testing to high-risk groups would
222 reduce 52% of severe cases by antivirals at $R_e = 1.5$, 500 tests/100K/day and 90%
223 vaccination coverage as opposed to 66% under the same scenario but without testing
224 restrictions. On the other hand, when operating under limited test availability relative to R_e ,
225 restricting symptomatic testing to high-risk individuals could be an effective strategy to
226 further reduce severe cases (i.e. Fold increase in proportion of severe cases averted relative to
227 no symptomatic testing restrictions when $R_e \geq 1.5$, across all vaccination coverages and
228 countries simulated: 100 tests/100K/day, median 4.9-fold (IQR = 3.3-6.4); 500
229 tests/100K/day, median 3.2-fold (IQR = 2.4-5.1)) and in turn, deaths as well (Figure S10). Of
230 the test distribution strategies simulated in this study, restricting testing to high-risk-groups-
231 only also substantially reduced the number of tests performed per antiviral distributed to
232 median 6 tests (IQR = 5-8 tests; Figure S11). In contrast, a median 20 tests (IQR = 15-33
233 tests) would be required per antiviral distributed if symptomatic testing was performed
234 without restrictions about risk status.

235

236 *Oral antiviral need*

237 Assuming that only symptomatic high-risk individuals who sought testing received an
238 antiviral course upon a positive test, and that there were two 90-day epidemic waves in a
239 year, we estimated that one antiviral course is needed for every 73-251 (14-154) persons per
240 year on average if testing rate was 100 (500) tests/100K/day across all simulated countries
241 and vaccination coverage (Figure 4). We assumed that vaccine protection against infection
242 was low (29%) and that antivirals were distributed regardless of vaccination status. As such,
243 increasing vaccination coverage did not lower antiviral need substantially (median 0.93-fold
244 change (IQR = 0.70-1.00) when vaccination coverage increased from 10% to 90%).
245 Conversely, the amount of antivirals distributed depends on R_e (median 2.60-fold change
246 (IQR = 0.97-4.35) when R_e increases from 0.9 to 2.0), country demographics (median 1.72-
247 fold change (IQR=1.02-2.04) when distributing antivirals in Georgia relative to Zambia),
248 testing rates (median 4.31-fold change (IQR = 1.49-5.77) when increasing from 100 to 500
249 tests/100K/day), and how tests were targeted (median 2.57-fold change (IQR = 1.52-4.55)
250 when testing only high-risk as opposed to all symptomatic individuals).

251

252 *Impact of oral antivirals with over-the-counter self-tests*

253 Unlike LMICs, over-the-counter Ag-RDTs were readily available in high-income countries
254 during and after the emergency phase of the pandemic. In a separate analysis for the
255 Netherlands, we assumed that over-the-counter Ag-RDTs for self-testing were widely
256 available (i.e. with no-cap on availability) such that only 10% of symptomatic individuals
257 seek clinic-provided testing directly. We also assumed that 80% of symptomatic individuals
258 who did not seek clinic-provided testing may perform a self-test using over-the-counter Ag-
259 RDTs instead. This effectively means that up to 82% of *all* symptomatic individuals would
260 perform either a clinic-provided or over-the-counter self-test. All high-risk individuals who
261 tested positive using self-tests would then seek reflexive testing at clinics on the same day to

262 be administered antivirals. Clinic-provided testing would only be performed if they were still
263 available under the average test availability of either 100 or 500 tests/100K/day.

264

265 Under these assumptions, we found that in combination with clinic-provided testing rate of
266 500 tests/100K/day, distribution of antivirals could avert 56-59% of severe cases and 67-70%
267 of deaths on average, regardless of the epidemic intensity (Figure 5). Reduction in infections
268 due to antivirals was similarly modest and did not amount to more than an average of 13%.
269 However, if mean clinic-provided testing rates fell to 100 tests/100K/day, the mean
270 proportion of severe cases and deaths averted would also drop precipitously to as low as 14%
271 and 19% respectively when $R_e \geq 1.5$. Across both testing rates and R_e , we found that one
272 antiviral course was distributed for every 4-69 individuals for two 90-day epidemic waves in
273 a year.

274

275 Since antivirals must be administered promptly upon a positive diagnosis, we also computed
276 the proportion of high-risk, symptomatic individuals that would miss the treatment window if
277 they had sought reflexive testing late. Regardless of clinical testing rate and R_e , for $\geq 90\%$ of
278 high-risk symptomatic individuals who were able to avert severe disease outcomes by
279 antivirals to be treated with the drug, they must not seek reflexive testing at clinics (if
280 reflexive testing is required) later than two days after being tested positive with over-the-
281 counter self-tests (Figure S12).

282

283 *Effectiveness of test-and-treat strategies*

284 To further compare the effectiveness of the test-and-treat strategies we investigated, we
285 plotted efficiency curves of the number of severe cases averted by antivirals against the
286 number of antivirals administered across all R_e values and countries (Figure S13). As we

287 assumed that there was no cap on antiviral availability, the limited test availability thus
288 determines the number of antivirals distributed and in turn, the maximum number of severe
289 cases averted by antivirals. We found that testing and treating test-positive, high-risk
290 household contacts alongside the test-positive index individual (“Symptomatic + HR
291 household” in Figure S13) was the least efficient test-and-treat strategy in our analyses. This
292 is because allocating tests to screen high-risk household contacts, who may or may not be
293 infected, under limited test availability reduced the number of tests that would otherwise have
294 been used to identify symptomatic infected high-risk individuals for antiviral administration.
295 Restricting tests to high-risk individuals only (“HR symptomatic only”) was similarly
296 effective to no restriction in access to tests for all symptomatic individuals (“Symptomatic”)
297 as it is an essentially a workaround of the latter strategy to increase the number of high-risk
298 infected individuals who are tested and treated under limited test-availability. In short, the
299 greater the access high-risk individuals have to testing, the more likely they could be
300 identified for timely treatment by antivirals. This could also be achieved when we test all
301 symptomatic individuals but ensuring the wide availability of over-the-counter self-tests
302 alongside large clinic-based test availability (“OTC self-test”).

303

304 *Sensitivity analyses*

305 We performed several sensitivity analyses in Georgia, owing to the relatively greater impact
306 of antivirals among the simulated LMICs, and investigated the extent to which our results
307 may deviate under different key assumptions. First, unvaccinated individuals could have
308 shared socio-demographic traits³² and consequently vaccinated individuals would not
309 necessarily be randomly distributed across the population. As an approximation, we assumed
310 that vaccinated individuals, while still tiered by age, cluster among members from the same
311 household. Although reduction in infections remained similarly modest even when

312 vaccinated individuals tended to be clustered (Figure S14), a larger proportion of severe cases
313 were averted by antivirals (50% vaccinated: 8% (random) vs. 30% (clustered); 90%
314 vaccinated: 14% (random) vs. 44% (clustered)) at the highest epidemic intensity simulated
315 ($R_e=2$) but only if testing rates were large enough to support the distribution of antivirals
316 (500 tests/100,000 people/day; Figure S15). However, the greater impact of antivirals on
317 severe cases here is attributed to the increased number of severe cases stemming from
318 vaccinated individuals being clustered (Figure S15B). We found that severe cases increased
319 by 15-170% across all simulated scenarios if vaccinated individuals were clustered by
320 households as opposed to being randomly assigned. This correspondingly led to greater oral
321 antiviral demand as well with one antiviral course distributed for every 53-128 (5-104)
322 persons per year if testing rate was 100 (500) tests/100K/day. In short, while oral antivirals
323 could alleviate the greater disease burden associated with clustering among vaccinated
324 individuals, it is only facilitated by large enough testing rates and the need for greater
325 antiviral supply. The more critical factor towards lowering severe cases is to minimize spatial
326 bias among vaccinated individuals.

327

328 Second, we had assumed low average estimates of vaccine effectiveness (i.e. 29% and 70%
329 protection against infection and severe disease respectively). However, vaccine effectiveness
330 can be improved by updating the vaccine strains to match circulating viruses or through
331 booster shots. We repeated our simulations with vaccines conferring greater effectiveness,
332 including known average protection against Delta-like (i.e. 52% and 96% protection against
333 infection and severe disease respectively) and wild-type SARS-CoV-2 viruses (i.e. 75% and
334 97% protection against infection and severe disease).¹⁹⁻²¹ Similar to our original results for
335 low vaccine effectiveness, use of antivirals could reduce transmissions in Georgia by up to
336 ~20% but only if testing rates were high (500 tests/100K/day; Figure S16). In contrast, the

337 proportion of severe cases averted due to antivirals became increasingly uncertain (i.e. wider
338 error bars in Figure S17). This was because improved vaccine effectiveness, on top of wider
339 vaccination coverage, substantially reduced the number of severe cases. Nonetheless,
340 regardless of vaccine effectiveness and coverage, meaningful reductions in severe cases by
341 antivirals could only be achieved with higher testing rates (≥ 100 tests/100K/day) to support
342 the administration of antivirals for infected high-risk individuals.

343

344 Third, we lowered the epidemic seeding condition from 1% to 0.1% such that antivirals were
345 distributed and used by the population earlier akin to the situation where Paxlovid is readily
346 available in certain countries. Although reduction in infections by antivirals continues to be
347 achieved only at higher testing rates, if antivirals were distributed earlier (i.e. starting from a
348 lower seeding condition), infections could be lowered by up to 30% even when test
349 availability was 100 tests/100K/day (e.g. At 100 tests/100K/day and 50% vaccination
350 coverage, only an average of 1% of infections were averted due to antivirals when $R_e = 1.5$
351 if the seeding condition was set to 1% but increased to 21% if seeding proportion was
352 lowered to 0.1%; Figure S18). The reduction in infections compounded the impact of
353 antivirals on severe case reduction: the proportion of severe disease averted due to antivirals
354 increased with improved outcomes at higher vaccination coverage (e.g. At 100
355 tests/100K/day and 50% vaccination coverage, only an average of 4% of severe cases were
356 averted due to antivirals when $R_e = 1.5$ if seeding condition was at 1% but increased to 47%
357 if seeding proportion was lowered to 0.1%; Figure S19). The lower seeding condition also led
358 to a fair proportion of severe cases averted at 10 tests/100K/day but with large uncertainty
359 (i.e. wider error bars in Figure S19A) and mostly only when $R_e < 1$ or at high vaccination
360 coverage (90%). This suggests that the benefit of antivirals can be further augmented by early
361 widespread adoption of test-and-treat programs.

362

363 Finally, the results above were predicated on crisis-period willingness-to-test behavior.

364 However, in many countries, the willingness of people to test has waned substantially in the
365 post-emergency phase of the pandemic. To investigate the consequences of this decline, we
366 repeated our simulations for all countries assuming that the likelihood a symptomatic
367 individual seek testing was 10% instead of the 65% assumed in the prior results (Figure S20).

368 Low willingness to test would substantial reduce the impact of potential test-and-treat
369 programs under all test availabilities, averting no more than ~10% of severe cases on average
370 in any country for all simulated R_e values and vaccination coverage.

371

372 **Discussion**

373 Individual-level data on the effectiveness of antivirals for reducing severe disease^{3,4} and the
374 modelling work presented here highlight that substantial reductions in COVID-19 disease
375 burden could arise from population-level test-and-treat programs. However, the low testing
376 rates in the post-emergency phase of the pandemic represent a profound impediment for
377 realizing the benefits of such programs. Most of the analyses described here focused on test
378 availability as the functional constraint on the development of test-and-treat programs and
379 this remains an issue in many LMICs. However, in many countries, regardless of socio-
380 economic status, the willingness of people to pursue testing for respiratory virus disease is
381 either low or declining and this presents challenges even when tests are available.

382

383 Given that antivirals are unlikely to have substantial impact on population-level
384 transmission,⁵ if the main objective of testing is to maximize the distribution of antivirals to
385 infected high-risk individuals, restricting clinic-based testing to only high-risk symptomatic
386 individuals at testing rates of 100 tests/100K/day could lead to 3.3-6.4-fold increase in

387 proportions of severe cases averted relative to the default scenario where no restrictions to
388 clinic-provided testing was imposed, provided that people are proactively seek testing.

389

390 It is also possible to require asymptomatic, high-risk household contacts of test-positive
391 symptomatic individuals to perform self-tests in order to initiate as many high-risk infected
392 individuals to early antiviral treatment as possible. However, setting aside tests to screen
393 high-risk household contacts under test availability constraints diminish the utility of tests
394 that would have otherwise been used to test symptomatic individuals who sought testing. In
395 turn, the proportion of severe cases and deaths averted due to antiviral distribution decrease
396 by a relative factor of two to ten-fold under this strategy. A potential workaround could be to
397 distribute antivirals to high-risk household contacts of test-positive individuals without the
398 need to confirm if the high-risk contacts were infected themselves by testing. However, this
399 would also increase the number of antiviral courses needed as well as result in wastage
400 among individuals who were not infected. A cost effectiveness analysis could be performed
401 to identify the most resource effective strategy but is beyond the scope of this work.

402

403 Assuming high willingness to test, ensuring the wide-availability of over-the-counter self-
404 tests could also lead to substantial reductions in severe cases (56-59%) and deaths (67-70%)
405 at $R_e \geq 1.5$ (e.g. BA.1 or BA.5 variant-like events). However, if reflexive testing is needed
406 for administration of antivirals, these reductions would only be possible if clinic-provided
407 testing is maintained at the mean HIC rate of 500 tests/100K/day. If clinical testing volumes
408 drop to 100 tests/100K/day, the expected reduction in severe cases and deaths attributable to
409 antivirals would fall to only 14% and 19% respectively in an epidemic wave initializing at
410 $R_e = 2.0$ (e.g. BA.1 variant-like event).

411

412 Our results suggest that regardless of the (test and antiviral) distribution strategy, an effective
413 test-and-treat program in any country requires large testing rates ($\gg 100$ tests/100K/day) that
414 are far beyond testing rates reported globally since 2023.⁹ In turn, increasing vaccination is
415 likely a more viable approach to lower severe cases than implementing large-scale test-and-
416 treat programs. To compare the vaccination coverage and the resource requirements needed
417 for test-and-treat to achieve the same reduction in disease burden, we computed the
418 additional vaccination coverage needed to halve the number of severe cases at different R_e
419 under 10% starting vaccination coverage. We also estimated the equivalent number of tests
420 and antivirals distributed to half the number of severe cases (Table 2). Across all countries
421 and R_e , we estimated that an additional 24%-67% of the population must be vaccinated to
422 reduce the number of severe cases by half without antivirals. Conversely, $\sim 9,000 - 400,000$
423 courses of antivirals per 1,000,000 people would be needed to avert the same number of
424 severe cases by antivirals for one epidemic wave. Furthermore, we estimated that $\sim 200 -$
425 $7,000$ tests must be performed per 100,000 people per day to support the distribution of those
426 antivirals. While these testing rates were achieved by some high-income countries during the
427 COVID-19 pandemic, no countries are testing at anywhere near these rates in the post-
428 emergency phase, suggesting that vaccination would likely be the more efficient option for
429 reducing severe disease burden.

430
431 There have been other modelling efforts that estimated substantial reductions in disease
432 burden by distributing antivirals to 20% - 50% of symptomatic infected individuals.
433 However, from our analyses, doing so would also require testing rates that are far greater than
434 500 tests/100,000 people/day. First, Leung et al.⁷ estimated that distributing antivirals to 50%
435 of all symptomatic infected individuals regardless of risk status would only reduce
436 hospitalizations by 10-13% in a population with high vaccination coverage (70-90%). For the

437 Netherlands, we simulated a population with 80% vaccination coverage and large test
438 availability, that included both clinic-based and over-the-counter self-tests, such that at least
439 50% of all symptomatic individuals were diagnosed. We estimated that 56-59% of severe
440 cases could be averted if only high-risk symptomatic individuals were administered
441 antivirals. When we reconfigured our simulations to now distribute antivirals to 50% of all
442 symptomatic infected individuals, the proportion of severe cases averted lower to only 18%
443 which is more in line with Leung et al.

444

445 Second, Matrajt et al. found that initiating 20% of infected individuals that were >65 years of
446 age on antivirals daily could avert 32-43% of deaths in an Omicron-like wave ($R_e \geq 2$) for an
447 unvaccinated population in LMICs such as Kenya and Mexico.⁵ We had estimated that 31-
448 62% of deaths could be averted at $R_e = 2$ at low (10%) vaccination coverage in LMICs but
449 only if test availability was 500 tests/100K/day and clinic-provided symptomatic testing were
450 restricted to high-risk individuals, which would mean a daily average of 19-20% of high-risk
451 infected individuals being initiated on treatment each day. If there are no restrictions on
452 access to clinic-provided tests, testing rate must be at least 750 tests/100K/day to initiate 20%
453 of infected >65-years on antivirals daily with >95% probability, indicating that the previous
454 from Martrajt et al. predicated on very high testing rates.

455

456 Finally, Brault et al. estimated that 11% of hospitalizations could be averted if antivirals with
457 50% effectiveness were administered to half of all high-risk cases in Wallis and Futuna,
458 where ~70% of individuals have at least two doses of vaccines, during an epidemic wave
459 with a doubling time of 2-3 days.⁸ In the closest scenario we had simulated (i.e $R_e = 2$, 46%
460 effectiveness of antivirals, 50% vaccination coverage and 500 tests/100K/day), we estimated
461 that severe cases could be reduced by 7% in Brazil (Figure 2B), which has a similar

462 demography to Wallis and Futuna (i.e. median age = 33 and 35 years in Brazil and Wallis and
463 Futuna respectively; proportion of individuals ≥ 65 years = 10% and 13% respectively).
464 However, like the two preceding examples, this is only possible at testing rates that are many-
465 fold higher than those performed in most LMICs both during and after the emergency-phase
466 of the pandemic.

467
468 There are limitations to our work: First, our simulations were based on the estimated
469 effectiveness of nirmatrelvir–ritonavir. We did not consider the clinical benefits of other oral
470 antivirals as nirmatrelvir–ritonavir was the most efficacious antiviral available during the
471 development of this work.

472
473 Second, as a simplification, we assumed that individuals with pre-existing comorbidities that
474 augment the risk of severe COVID-19 disease outcomes were randomly distributed across the
475 population. The prevalence of certain comorbidities is known to correlate with socio-
476 economic and demographic factors,^{33,34} resulting in the clustering of severe cases with similar
477 socio-economic backgrounds. However, there is limited country-specific data on the
478 prevalence and distribution of comorbidities across the population, especially for LMICs. We
479 would also need to stratify the simulation population socio-economically which is beyond the
480 scope of this study.

481
482 Third, we had assumed that clinical testing for disease and administration of treatment occur
483 on the same day in our simulations. However, any practical barriers that limit timely access to
484 antivirals (e.g. inadequate supply and distribution, limited access to healthcare providers,
485 acceptance of antiviral therapy) can substantially reduce the estimated impact of test-and-
486 treat programs.³⁵ As shown in Figure S12, even under a large test availability scenario (with

487 self-tests), if administration of antivirals was delayed by >2 days, <20% of high-risk treated
488 individuals received their antiviral courses within the 5 days post-symptom onset window
489 when Paxlovid was reported to be efficacious. As such, even if testing rates could sufficiently
490 support test-and-treat programs, delays in accessing antivirals, which had been reported in
491 various LMICs,³⁶ must be minimized for these programs to remain effective. Ideally, testing
492 and treatment of infected patients should occur at the same clinical interaction.

493

494 Next, others have showed that with greater vaccine effectiveness against infection (60%), a
495 high vaccination coverage (~70-80%) coupled with antivirals that have an effect in lowering
496 transmissions could synergistically reduce infections in the population.⁵ However, for only
497 ~20% of infections to be averted in an Omicron-like wave (i.e. doubling time of 2-3 days³⁷),
498 the antiviral must block onward transmission completely after initiating treatment and 30% of
499 symptomatic infected adults must be administered antivirals daily.⁵ Even if an antiviral that is
500 100% effective in truncating transmissions exist and there was high willingness to test, the
501 testing rate must at least be 764 tests/100K/day to initiate 30% of symptomatic infected
502 individuals to treatment daily with >95% probability based on our estimates.

503

504 Finally, we did not factor in changes to individual immunity levels due to previous infections
505 or immune waning. As a simplification, we assumed that these effects have been implicitly
506 captured by various initial R_e values and were able to simulate epidemics with prevalence
507 ranges similar to those reported during the spread of Omicron subvariants BA.5 and XBB.1.5
508 (Figure S1). However, it is currently unclear how changing immunity dynamics in the future
509 could affect severe disease outcomes.

510

511 Taken all together, while test-and-treat programs have substantial theoretical utility for
512 reducing population-level burden of disease, there remain fundamental challenges in terms of
513 the availability of diagnostics and the willingness of people to seek testing in general and
514 particularly within the relatively short window of effectiveness of the antivirals considered
515 here. The potential benefits and resource requirements of test-and-treat programs must also
516 be carefully considered if budget constraints make vaccination programs a competing
517 interest.

518

519 **Methods**

520 *The PATAT simulation model*

521 PATAT creates an age-structured population of individuals within contact networks of multi-
522 generational households, schools, workplaces, regular mass gatherings (e.g. religious
523 gatherings) and random community settings with country-specific demographic data (see
524 Supplementary Text). Epidemic simulations begin with 1% of the population infected with
525 SARS-CoV-2 and compute transmissions between individuals across different contact
526 networks each day. The computational flow of a PATAT simulation is summarised as
527 follows: First, an age-structured population of agents is created. Close contact networks are
528 subsequently created based on the given demographic data. The simulation is then initialised
529 and iterates over a given period of time where each time step corresponds to a day. The
530 operations during each timestep encompass updating the disease progression of infected
531 individuals, the status of isolated/quarantined agents, application of community testing
532 strategies and computation of transmission events within contact networks.

533

534 PATAT implements a SEIRD epidemic model where the simulated population is
535 distinguished between five compartments: susceptible, exposed (i.e. infected but is not

536 infectious yet; latent phase), infected (which include the presymptomatic infectious period for
537 symptomatic agents), recovered and dead. The infected compartments are further stratified by
538 their presented symptoms, including asymptomatic, presymptomatic, symptomatic mild or
539 severe. All symptomatic agents will also first undergo an infectious presymptomatic period
540 after the exposed latent period. They will either develop mild symptoms who will always
541 recover from the disease or experience severe infection which could either lead to death or
542 recovery. As a simplification, PATAT assumes that all agents presenting severe symptoms
543 are sufficiently isolated from the population (e.g. through hospitalization) that they are
544 unlikely to contribute to further transmissions.

545

546 When an infectious agent i comes into contact with a susceptible individual j , the probability
547 of transmission ($p_{transmission,(i,j)}$) is given by:

$$548 \quad p_{transmission,(i,j)} = \beta \times \Phi_i \times f_c \times f_{asympt,i} \times f_{load,i} \times f_{immunity,j} \times f_{susceptibility,j} \times \rho_i \times \rho_j$$

549 where β is the base transmission probability per contact, Φ_i is the overdispersion factor
550 modelling individual-level variation in secondary transmissions (i.e. superspreading events),
551 f_c is a relative weight adjusting β for the network setting c where the contact has occurred,
552 $f_{asympt,i}$ is the assumed relative transmissibility factor if infector i is asymptomatic,
553 $f_{immunity,j}$ measures the immunity level of susceptible j against the transmitted virus (i.e.
554 $f_{immunity,j} = 1$ if completely naïve; $f_{immunity,j} = 0$ if fully protected), $f_{susceptibility,j}$ is the
555 age-dependent susceptibility of j , ρ_i and ρ_j are the contact rates of infector i and susceptible
556 j respectively.

557

558 Φ_i is randomly drawn from a negative binomial distribution with mean of 1.0 and shape
559 parameter of 0.45.³⁸ As evidence have been mixed as to whether asymptomatic agents are
560 less transmissible, we conservatively assume there is no difference relative to symptomatic

561 patients (i.e. $f_{asympt,i} = 1$). The age-structured relative susceptibility values $f_{susceptibility,j}$ are
562 derived from odds ratios reported by Zhang et al.²² (Table S1).

563

564 β is determined by running initial test simulations with a range of values on a naïve
565 population with no interventions that would satisfy the target reproduction number as
566 computed from the resulting exponential growth rate and distribution of generation
567 intervals.³⁹ f_c is similarly calibrated during these test runs such that the transmission
568 probabilities in households, workplaces, schools, and all other community contacts are
569 constrained by a relative weighting of 10:2:2:1.²³

570

571 The total duration of infection since exposure depends on the symptoms presented by the
572 patient and is comprised of different phases (i.e. latent, asymptomatic, presymptomatic,
573 onset-to-recovery/death). The time period of each phase is drawn can be found in Table S1.

574 For each infected individual, PATAT randomly draws a within-host viral load trajectory over
575 the duration of infection, which impacts the sensitivity of Ag-RDTs⁴⁰, based on known
576 distributions for Omicron BA.1⁴¹. Similar viral load trajectories were drawn for both
577 asymptomatic and symptomatic infected individuals⁴² using a stochastic model modified
578 from the one previously developed by Quilty et al.⁴³ A baseline Ct value ($Ct_{baseline}$) of 40 is
579 established upon exposure. The infected agent becomes infectious upon the end of the latent
580 period and their Ct value is assumed to be ≤ 30 . A peak Ct value is then randomly drawn
581 from a normal distribution (Table S1). Peak Ct is assumed to occur upon symptom onset for
582 symptomatic agents and one day after the latent period for asymptomatic individuals.

583 Cessation of viral shedding (i.e. return to $Ct_{baseline}$) occurs upon recovery or death. PATAT
584 assumes that the transition rate towards peak Ct value should not be drastically different to
585 that when returning to baseline upon cessation (i.e. there should be no sharp increase to

586 baseline Ct value after gradual decrease to peak Ct value or vice versa). As such, the time
587 periods of the different phases of infection are randomly drawn from the same quintile of
588 their respective sample distribution. The viral load trajectory is then simulated by fitting a
589 cubic Hermite spline to the generated exposed ($t_{exposed}$, $Ct_{baseline}$), latent (t_{latent} ,
590 $Ct_{latent} = 30$), peak (t_{peak} , Ct_{peak}) and cessation values ($t_{recovered/death}$, $Ct_{baseline}$). The
591 slope of the fitted curve is assumed to be zero for all of them except during t_{latent} where its
592 slope is assumed to be $\frac{Ct_{peak}-Ct_{baseline}}{t_{peak}-t_{exposed}}$. PATAT then uses the fitted trajectory to linearly
593 interpolate the viral load transmissibility factor ($f_{load,i}$) of an infectious agent i assuming that
594 they are twice as transmissible at peak Ct value (i.e. $f_{load} = 2$) relative to when they first
595 become infectious (i.e. Ct value = 30; $f_{load} = 1$).

596

597 Unlike PCR which is highly sensitive due to prior amplification of viral genetic materials, the
598 sensitivity of Ag-RDT will depend on the viral load of the tested patient. While the
599 specificity of Ag-RDT is assumed to be 98.9%, its sensitivity depends on the Ct values of the
600 tested infected agent: Ct > 35 (0%); 35 – 30 (20.9%); 29 – 25 (50.7%); Ct ≤ 24 (95.8%).⁴⁰

601

602 We assumed that agents would change their behaviour when (i) they start to present
603 symptoms and go into self-isolation (10% compliance assumed, 71% endpoint adherence)²⁷;
604 (ii) they test positive and are isolated for 10 days (50% compliance assumed, 86% endpoint
605 adherence)²⁷; or (iii) they are household members (without symptoms) of positively-tested
606 agents and are required to be in quarantine for 14 days (50% compliance assumed, 28%
607 endpoint adherence)²⁷. Once an agent goes into isolation/quarantine, we linearly interpolate
608 their probability of adherence to stay in isolation/quarantine over the respective period. Given
609 the lack of infrastructure and resources to set up dedicated isolation/quarantine facilities in
610 many LMICs, we assumed that all isolated and quarantined individuals would do so at home.

611
612 We simulated 90-day epidemic waves in a community of 1,000,000 individuals using
613 demographic data collected from three LMICs (i.e. Brazil, Georgia, Zambia) and the
614 Netherlands as a HIC counterpart. We simulated different vaccination coverage (10%, 50%
615 and 90%) for all countries for comparability. In the separate analysis examining how
616 widespread availability of over-the-counter self-tests could impact test-and-treat programs in
617 HICs, we assumed that 80% of the population was vaccinated in the Netherlands based on
618 estimates on July 2022,⁴⁴ which is largely comparable to other HICs.⁴⁵ As a simplification,
619 we assumed that vaccination protection rates against infection and severe disease were 29%
620 and 70% respectively, which were based on the more conservative, lower average estimates
621 of vaccine effectiveness against BA.1 across different vaccines (i.e. mRNA and ChAdOx1
622 nCoV-19 vaccine) and doses (i.e. 1-3 doses).¹⁹⁻²¹ We did not assume a specific protection
623 rate against death since the referenced studies had reported effectiveness estimates against
624 severe disease outcomes which include hospitalization and/or death. Nonetheless, protection
625 of deaths is implicitly accounted for since individuals could only die from COVID-19 if they
626 had progressed to severe disease in the model.

627

628 *Diagnostic testing*

629 In the model, individuals with symptomatic COVID-19 have a probability of seeking testing
630 at a healthcare facility. We also estimated symptomatic testing demand from individuals
631 without COVID-19 who sought clinic-provided testing (e.g. individuals who present with
632 similar respiratory symptoms): Based on the range of test positivity rates reported by various
633 countries during the second-half of 2021 (when community testing was assumed to still be
634 prevalent in most countries),⁴⁵ we assumed that test positivity rate was 10% at the start as

635 well as end of an epidemic wave, and a 20% test positivity rate at the peak, linearly
636 interpolating the demand for periods between these time points.^{11,12}

637

638 We also simulated scenarios where household contacts of clinic-provided positively-tested
639 individuals were given Ag-RDTs for self-testing for three consecutive days following the
640 positive clinical test of the latter. Adherence (likelihood) to testing by asymptomatic
641 household contacts was assumed to decrease linearly to 50% by the third day. We also
642 simulated an alternative test distribution strategy where we restricted clinic-provided
643 symptomatic testing to high-risk individuals only.

644

645 We performed simulations under three levels of average test availability at healthcare clinics:
646 10 (mean LMIC testing rate as of Q2/2022),⁹ 100 and 500 (mean HIC testing rate as of
647 Q2/2022)⁹ tests/100K/day. Regardless if symptomatic individuals choose to self-isolate, after
648 $\tau_{delay, symp-test}$ days from symptom onset, the symptomatic agent may decide to get tested
649 with a Bernoulli probability of $p_{symp-test}$. PATAT assumes that agents who have decided
650 against symptomatic testing (i.e. failed Bernoulli trial) or received negative test results will
651 not seek symptomatic testing again. We assumed that average $p_{symp-test} = 65\%$ on average
652 based on surveys of test-seeking behaviour during the COVID-19 pandemic.^{30,31} In other
653 words, there is an average 65% chance that an individual with mild symptom would seek
654 clinic-provided testing and were only tested if there were available test stocks. We lowered
655 $p_{symp-test}$ to 10% in a sensitivity analysis to estimate the impact of test-and-treat programs
656 under waning willingness to test.

657

658 In the separate analysis where over-the-counter self-tests were available in the Netherlands,
659 we assumed that only 10% of mild symptomatic individuals in the Netherlands would seek

660 clinic-provided testing upon symptom onset based on average daily testing rates reported by
661 all Dutch municipal health services in 2021-Q1/2022 (i.e. approximately up to the end of the
662 Omicron BA.1 wave; 7551 tests/100K/day) and Q2/2022 (post Omicron BA.1 wave; 641
663 tests/100K/day).⁴⁶ We assumed that 50% or 80% of individuals who opted not to seek clinic-
664 provided testing would perform a self-test using an over-the-counter Ag-RDT. We assumed
665 that all high-risk individuals who tested positive would then seek reflexive testing at clinics
666 to be disbursed an antiviral course.

667

668 *Oral antivirals*

669 Regardless of their vaccination status (per WHO guidance),⁴⁷ all high-risk individuals who
670 tested positive within five days after symptom onset were eligible for a course of antiviral
671 therapy.^{3,4} We did not impose any caps on antiviral availability as we wanted to estimate the
672 potential number of antiviral courses needed and thus their maximum achievable impact on
673 epidemic outcomes under different levels of test availability and antiviral distribution
674 strategies. We did not factor any risk reduction in transmissions or deaths given the lack and
675 low certainty of evidence of the impact of oral antivirals on protection against transmission
676 and mortality respectively.⁴⁷ However, individuals could only die from COVID-19 if they
677 had progressed to severe disease in our model.

678

679 For individuals who were treated with antivirals that were simulated to result in severe
680 disease, we performed a Bernoulli trial with the probability of averting severe disease (i.e.
681 46%), provided that they were currently in the presymptomatic phase or were experiencing
682 mild disease. If the Bernoulli trial succeeded, we re-simulated their disease progression and
683 within-host viral dynamics using the procedures above but now under the assumption that
684 they would develop only mild disease and conditioning that the maximum viral load is lower

685 than before. Changes were only made to the upcoming phases of disease progression from the
686 then current phase of infection. The average recovery period of having mild symptoms was
687 assumed to be 5.4 days as opposed to 18.1 days when presenting severe disease.^{41,48} In turn,
688 while we did not parameterize the impact on transmission reduction by antivirals, the
689 shortened recovery, and thus infectious period as well as lower maximum viral load of
690 individuals who were effectively treated could result indirect reduction in onward
691 transmissions.

692

693 We performed five independent simulations for each combination of parameters described
694 above. All key parameters are tabulated in Table S1. Further details of PATAT are described
695 in Han et al.^{11,12} and the Supplementary Information. The PATAT model source code is
696 available at <https://github.com/AMC-LAEB/PATAT-sim>.

697

698 **Data and code availability:**

699 All data relevant to the study are included in the Article, the Supplementary Information and
700 the GitHub repository (<https://github.com/AMC-LAEB/PATAT-sim>). The PATAT model
701 source code can also be found in the GitHub repository
702 (<https://github.com/AMC-LAEB/PATAT-sim>).

703

704 **Acknowledgements:**

705 This work was supported by the European Research Council [NaviFlu 818353 to A.X.H. and
706 C.A.R.], the National Institutes of Health [5R01AI132362-04 to C.A.R.] and the Dutch
707 Research Council (Nederlandse Organisatie voor Wetenschappelijk Onderzoek) [Vici
708 09150182010027 to C.A.R.]. This work was supported by the Rockefeller Foundation, and
709 the Governments of Germany, Canada, UK, Australia, Norway, Saudi Arabia, Kuwait,

710 Netherlands and Portugal [all authors]. The authors are pleased to acknowledge that all
711 computational work reported in this paper was performed on the Shared Computing Cluster
712 which is administered by Boston University's Research Computing Services
713 (www.bu.edu/tech/support/research/).

714

715 **Authors' contributions:**

716 Conceptualization: A.X.H., E.H., S.C., B.R., B.E.N., C.A.R.

717 Methodology: A.X.H., B.E.N., C.A.R.

718 Software: A.X.H.

719 Validation: A.X.H., E.H., S.C., B.R., B.E.N., C.A.R.

720 Formal analysis: A.X.H.

721 Investigation: A.X.H., B.E.N., C.A.R.

722 Resources: B.E.N., C.A.R.

723 Data curation: A.X.H., B.E.N., C.A.R.

724 Writing – original draft: A.X.H., B.E.N., C.A.R.

725 Writing – review & editing: A.X.H., E.H., S.C., B.R., B.E.N., C.A.R.

726 Visualization: A.X.H., B.E.N., C.A.R.

727 Supervision: B.E.N., C.A.R.

728 Project administration: B.E.N., C.A.R.

729 Funding acquisition: E.H., S.C., B.R., B.E.N., C.A.R.

730

731 **Declaration of interests:**

732 The authors declare that they have no competing interests.

733

734 **Figure legends**

735 **Figure 1: Demography of simulated countries.** (a) Bar plot shows the age distribution of
736 each simulated country archetype (Low and middle-income countries (LMICs): Brazil,
737 Georgia, Zambia; High-income country: Netherlands) stratified in 5-year bins. Each dashed
738 black line in the Brazil, Georgia and Zambia plots denotes the age distribution of one of 132
739 other LMICs¹⁴ that best matches (i.e. lowest mean absolute error) the age distribution of the
740 simulated country archetype. Age distribution of the population in each country is
741 downloaded from World Population Prospects compiled by the United Nations¹⁵. (b)
742 Heatmap showing the normalized relative contact rates between individuals of different age
743 groups in 5-year bins averaged across all contact networks generated by the PATAT
744 simulation model.

745
746 **Figure 2: Impact of test-and-treat on severe cases.** No restrictions on access to
747 symptomatic testing at clinics (i.e. all symptomatic individuals who sought testing at clinics
748 would receive one if in stock) and high-risk household contacts of test-positive individuals
749 are not tested. All eligible high-risk individuals (i.e. ≥ 60 years of age or an adult ≥ 18 years
750 with a relevant comorbidity) who tested positive were given a course of oral antivirals. Line
751 plots (left y -axis) show the percentage change in severe cases relative to no distribution of
752 antivirals under different levels of mean test availability (different shades of color) after a 90-
753 day epidemic wave in a population of 1,000,000 individuals with (a) 10%, (b) 50%, and (c)
754 90% vaccination coverage for different epidemic intensities (measured by the initial effective
755 reproduction number (R_e); x -axis). Bar plots (right y -axis) show the number of severe cases
756 in each corresponding scenario. The dotted outline of each bar shows the number of severe
757 cases of each scenario when no antivirals were distributed.

758

759 **Figure 3: Impact of test-and-treat on severe cases when restricting symptomatic testing**
760 **to high-risk individuals only.** High-risk household contacts of test-positive individuals are
761 not tested. All eligible high-risk individuals (i.e. ≥ 60 years of age or an adult ≥ 18 years with
762 a relevant comorbidity) who tested positive were given a course of oral antivirals. Line plots
763 (left **y**-axis) show the percentage change in severe cases relative to no distribution of
764 antivirals under different levels of mean test availability (different shades of color) after a 90-
765 day epidemic wave in a population of 1,000,000 individuals with (a) 10%, (b) 50%, and (c)
766 90% vaccination coverage for different epidemic intensities (measured by the initial effective
767 reproduction number (R_e); **x**-axis). Bar plots (right **y**-axis) show the number of severe cases
768 in each corresponding scenario. The dotted outline of each bar shows the number of severe
769 cases of each scenario when no antivirals were distributed.

770
771 **Figure 4: Estimated need of oral antivirals.** Line plots show the ratio of estimated oral
772 antiviral courses needed to number of people per year (expressed as 1 oral antiviral course
773 per **n** number of individuals; assuming two epidemic waves a year) in simulated countries
774 (color) under different simulated scenarios (i.e. testing rate at 100 or 500 tests/100,000
775 people/day (shading and linestyle) and distribution modality (left plot panel: test all
776 symptomatic individuals who sought testing at clinics; middle plot panel: test all
777 symptomatic individuals who sought testing as well as distributing clinic-provided self-tests
778 to high-risk asymptomatic household contacts of test-positive individuals; right plot panel:
779 test only high-risk symptomatic individuals who sought testing at clinics). All test-positive
780 eligible high-risk individuals from clinic-provided testing would receive a course of oral
781 antivirals. (a) 10%, (b) 50% and (c) 90% vaccination coverage assumed for the simulated
782 population.

783

784 **Figure 5: Impact of test-and-treat in a high-income country (Netherlands) with wide**
785 **availability of over-the-counter self-tests.** No restrictions on access to symptomatic testing
786 at clinics (i.e. all symptomatic individuals who sought testing at clinics would receive one if
787 in stock) and high-risk household contacts of test-positive individuals are not tested. Over-
788 the-counter antigen rapid diagnostic tests (Ag-RDTs) are assumed to be widely available with
789 unlimited stocks. As such, we assumed that only 10% of symptomatic individuals would seek
790 clinical testing directly while 80% of those who opted not to seek clinic-provided testing
791 would perform self-testing using over-the-counter Ag-RDTs. All high-risk individuals who
792 tested positive through self-testing would seek reflexive testing at clinics on the same day.
793 All eligible high-risk individuals (i.e. ≥ 60 years of age or an adult ≥ 18 years with a relevant
794 comorbidity) who tested positive at clinics, either directly or through reflexive testing, were
795 given a course of oral antivirals. Line plots (left **y**-axis) show the percentage change in (a)
796 total infections, (b) severe cases and (c) deaths relative to no distribution of antivirals under
797 different clinical testing rates (different shades of color) after a 90-day SARS-CoV-2
798 epidemic wave in a population of 1,000,000 individuals with 80% vaccination coverage for
799 different epidemic intensities (measured by the initial effective reproduction number (R_e); **x**-
800 axis). Bar plots (right **y**-axis) show the number of severe cases in each corresponding
801 scenario. The dotted outline of each bar shows the number of severe cases of each scenario
802 when no antivirals were distributed.

803

804

805 **Tables**

806 **Table 1: Number and proportion of severe cases averted due to distribution of oral**
 807 **antivirals at 10% and 90% vaccination coverage.** No restrictions on access to symptomatic
 808 testing at clinics (i.e. all symptomatic individuals who sought testing at clinics would receive
 809 one if in stock) and high-risk household contacts of test-positive individuals are not tested.
 810

Country	Testing rate (tests/100,000 people/day)	R_e	10% vaccination coverage		90% vaccination coverage	
			No. of severe cases averted	Proportion of severe cases averted	No. of severe cases averted	Proportion of severe cases averted
Zambia	10	0.9	29	2.7	3	1.1
		1.2	16	0.3	20	1.1
		1.5	0	0.0	0	0.0
		2.0	22	0.2	32	0.7
	100	0.9	147	16.9	48	20.1
		1.2	170	3.3	72	4.4
		1.5	172	1.9	131	3.7
		2.0	0	0.0	0	0.0
	500	0.9	242	35.0	102	45.6
		1.2	1053	26.5	441	38.0
		1.5	780	9.0	527	16.4
		2.0	824	7.2	433	8.8
Brazil	10	0.9	0	0.0	0	0.0
		1.2	0	0.0	0	0.0
		1.5	0	0.0	0	0.0
		2.0	0	0.0	0	0.0
	100	0.9	303	23.7	133	54.6
		1.2	623	6.4	195	13.6
		1.5	245	1.2	196	3.7
		2.0	0	0.0	0	0.0
	500	0.9	511	47.4	134	55.3
		1.2	2739	43.1	545	55.4
		1.5	2005	10.7	1404	35.7
		2.0	1553	6.1	872	9.4
Georgia	10	0.9	0	0.0	0	0.0
		1.2	0	0.0	0	0.0
		1.5	163	0.4	80	1.2

		2.0	0	0.0	0	0.0
	100	0.9	635	49.9	170	65.3
		1.2	1459	13.4	336	29.6
		1.5	929	2.6	483	8.7
		2.0	0	0.0	0	0.0
	500	0.9	792	63.4	167	63.5
		1.2	4344	65.3	597	66.9
		1.5	7481	24.3	2270	66.1
		2.0	4435	8.4	2115	13.6
Netherlands	10	0.9	0	0.0	0	0.0
		1.2	0	0.0	0	0.0
		1.5	0	0.0	21	0.2
		2.0	0	0.0	0	0.0
	100	0.9	598	48.2	171	66.6
		1.2	2333	20.1	362	30.7
		1.5	953	2.7	419	7.5
		2.0	0	0.0	0	0.0
	500	0.9	811	63.1	185	67.0
		1.2	4857	68.5	604	67.3
		1.5	8947	28.0	2123	65.1
		2.0	3190	5.9	2960	18.1

811

812

813

814 **Table 2: Vaccination coverage and test-and-treat requirements to half the number of**
 815 **severe cases at 10% pre-existing vaccination coverage.** For vaccination, the additional
 816 number of individuals per 1,000,000 people that must be vaccinated on top of the 10% pre-
 817 existing vaccination coverage is tabulated. For test-and-treat, there are no restrictions on
 818 access to symptomatic testing at clinics (i.e. all symptomatic individuals who sought testing
 819 at clinics would receive one if in stock) and high-risk household contacts of test-positive
 820 individuals are not tested.

821

Country	R_e	Vaccination		Test-and-treat	
		No. of vaccinated individuals per 1,000,000 people	No. of antivirals distributed per 1,000,000 people	Testing rate (tests/100,000 people/day)	
Zambia	1.2	496,192	18,436	545	
	1.5	586,432	60,370	2,185	
	2.0	665,567	113,835	4,383	
Brazil	1.2	312,095	15,494	316	
	1.5	437,067	82,093	1,760	
	2.0	566,068	197,465	4,751	
Georgia	1.2	253,988	9,246	166	
	1.5	317,855	52,499	721	
	2.0	477,855	211,977	3,471	
Netherlands	1.2	240,271	8,758	206	
	1.5	319,695	49,952	701	
	2.0	474,469	394,414	6,802	

822

823

824

825

826 **Supplemental information**

827 Document S1. Supplementary Text; Figures S1-S20; Table S1.

828

829 **References**

- 830 1. Singh, M. & de Wit, E. Antiviral agents for the treatment of COVID-19: Progress and
831 challenges. *Cell Rep Med* **3**, 100549 (2022).
- 832 2. Jayk Bernal, A. *et al.* Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized
833 Patients. *New England Journal of Medicine* **386**, 509–520 (2022).
- 834 3. Hammond, J. *et al.* Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with
835 Covid-19. *New England Journal of Medicine* **386**, 1397–1408 (2022).
- 836 4. Najjar-Debbiny, R. *et al.* Effectiveness of Paxlovid in Reducing Severe Coronavirus
837 Disease 2019 and Mortality in High-Risk Patients. *Clinical Infectious Diseases* (2022)
838 doi:10.1093/CID/CIAC443.
- 839 5. Matrajt, L., Brown, E. R., Cohen, M. S., Dimitrov, D. & Janes, H. Could widespread
840 use of antiviral treatment curb the COVID-19 pandemic? A modeling study. *BMC*
841 *Infect Dis* **22**, 1–16 (2022).
- 842 6. Usher, A. D. The global COVID-19 treatment divide. *The Lancet* **399**, 779–782
843 (2022).
- 844 7. Leung, K., Jit, M., Leung, G. M. & Wu, J. T. The allocation of COVID-19 vaccines
845 and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and
846 Pacific region: A modelling study. *Lancet Reg Health West Pac* **21**, 100389 (2022).
- 847 8. Brault, A. *et al.* Modelling the end of a Zero-COVID strategy using
848 nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna. *Lancet Reg Health*
849 *West Pac* **30**, (2023).

- 850 9. FIND. Test tracker - FIND. <https://www.finddx.org/covid-19/test-tracker/> (2022).
- 851 10. Gill, C. J. *et al.* What is the prevalence of COVID-19 detection by PCR among
852 deceased individuals in Lusaka, Zambia? A postmortem surveillance study. *BMJ Open*
853 **12**, (2022).
- 854 11. Han, A. X. *et al.* Strategies for using antigen rapid diagnostic tests to reduce
855 transmission of SARS-CoV-2 in low- and middle-income countries: a mathematical
856 modelling study applied to Zambia. *Clinical Infectious Diseases* (2022)
857 doi:10.1093/CID/CIAC814.
- 858 12. Han, A. X. *et al.* SARS-CoV-2 diagnostic testing rates determine the sensitivity of
859 genomic surveillance programs. *Nature Genetics* 2023 55:1 **55**, 26–33 (2023).
- 860 13. Wroe, E. B., Seung, K. J., Baker, B. K. & Farmer, P. E. Test and treat: a missing link
861 in the global fight against COVID-19. *Lancet Glob Health* **10**, e181–e182 (2022).
- 862 14. World Bank Country and Lending Groups – World Bank Data Help Desk.
863 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
864 [country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).
- 865 15. World Population Prospects - Population Division - United Nations.
866 <https://population.un.org/wpp/Download/Standard/MostUsed/>.
- 867 16. Mefsin, Y. M. *et al.* Epidemiology of Infections with SARS-CoV-2 Omicron BA.2
868 Variant, Hong Kong, January–March 2022 - Volume 28, Number 9—September 2022
869 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis* **28**, 1856–1858
870 (2022).
- 871 17. Tegally, H. *et al.* Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in
872 South Africa. *Nat Med* **28**, (2022).
- 873 18. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under
874 investigation in England: Technical briefing 50. (2023).

- 875 19. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529)
876 Variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- 877 20. Buchan, S. A. *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta
878 symptomatic infection and severe outcomes. *medRxiv* 2021.12.30.21268565 (2022)
879 doi:10.1101/2021.12.30.21268565.
- 880 21. Tseng, H. F. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and
881 Delta variants. *Nature Medicine* 2022 28:5 **28**, 1063–1071 (2022).
- 882 22. Zhang, J. *et al.* Changes in contact patterns shape the dynamics of the COVID-19
883 outbreak in China. *Science (1979)* **368**, 1481–1486 (2020).
- 884 23. Kerr, C. C. *et al.* Covasim: An agent-based model of COVID-19 dynamics and
885 interventions. *PLoS Comput Biol* **17**, e1009149- (2021).
- 886 24. Verity, R. *et al.* Estimates of the severity of coronavirus disease 2019: a model-based
887 analysis. *Lancet Infect Dis* **20**, 669–677 (2020).
- 888 25. Ferguson, N. M. *et al.* Report 9: Impact of non-pharmaceutical interventions (NPIs) to
889 reduce COVID-19 mortality and healthcare demand. (2020) doi:10.25561/77482.
- 890 26. O’Driscoll, M. *et al.* Age-specific mortality and immunity patterns of SARS-CoV-2.
891 *Nature* 2020 590:7844 **590**, 140–145 (2020).
- 892 27. Brazeau, N. F. *et al.* Report 34 - COVID-19 Infection Fatality Ratio Estimates from
893 Seroprevalence | Faculty of Medicine | Imperial College London. (2020)
894 doi:10.25561/83545.
- 895 28. Rawshani, A. *et al.* Severe COVID-19 in people with type 1 and type 2 diabetes in
896 Sweden: A nationwide retrospective cohort study. *The Lancet Regional Health -*
897 *Europe* **4**, (2021).


- 898 29. Bertagnolio, S. *et al.* Clinical features of, and risk factors for, severe or fatal COVID-
899 19 among people living with HIV admitted to hospital: analysis of data from the WHO
900 Global Clinical Platform of COVID-19. *Lancet HIV* **9**, e486–e495 (2022).
- 901 30. Rijksinstituut voor Volksgezondheid en Milieu. Research on behavioural rules and
902 well-being: round 3. [https://www.rivm.nl/en/behavioural-science-and-covid-19/results-](https://www.rivm.nl/en/behavioural-science-and-covid-19/results-of-study-behavioural-measures-and-well-being/round-3)
903 [of-study-behavioural-measures-and-well-being/round-3](https://www.rivm.nl/en/behavioural-science-and-covid-19/results-of-study-behavioural-measures-and-well-being/round-3) (2020).
- 904 31. Siegler, A. J. *et al.* Willingness to seek diagnostic testing for SARS-CoV-2 with home,
905 drive-through, and clinic-based specimen collection locations. *Open Forum Infect Dis*
906 **7**, (2020).
- 907 32. Alvarez-Zuzek, L. G., Zipfel, C. M. & Bansal, S. Spatial clustering in vaccination
908 hesitancy: The role of social influence and social selection. *PLoS Comput Biol* **18**,
909 (2022).
- 910 33. Ante-Testard, P. A. *et al.* Temporal trends in socioeconomic inequalities in HIV
911 testing: an analysis of cross-sectional surveys from 16 sub-Saharan African countries.
912 *Lancet Glob Health* **8**, (2020).
- 913 34. Mendenhall, E., Kohrt, B. A., Norris, S. A., Ndetei, D. & Prabhakaran, D. Non-
914 communicable disease syndemics: poverty, depression, and diabetes among low-
915 income populations. *The Lancet* vol. 389 Preprint at [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(17)30402-6)
916 [6736\(17\)30402-6](https://doi.org/10.1016/S0140-6736(17)30402-6) (2017).
- 917 35. Gold, J. A. W. *et al.* Dispensing of Oral Antiviral Drugs for Treatment of COVID-19
918 by Zip Code–Level Social Vulnerability — United States, December 23, 2021–May
919 21, 2022. *MMWR Morb Mortal Wkly Rep* **71**, (2022).
- 920 36. World Health Organization. Update on the rollout of COVID-19 tools: a report from
921 the ACT-A Tracking & Monitoring Task Force - 15 February 2023.

- 922 [https://www.who.int/publications/m/item/update-on-the-rollout-of-covid-19-tools--a-](https://www.who.int/publications/m/item/update-on-the-rollout-of-covid-19-tools--a-report-from-the-act-a-tracking---monitoring-task-force---15-february-2023)
923 [report-from-the-act-a-tracking---monitoring-task-force---15-february-2023](https://www.who.int/publications/m/item/update-on-the-rollout-of-covid-19-tools--a-report-from-the-act-a-tracking---monitoring-task-force---15-february-2023) (2023).
- 924 37. Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in
925 southern Africa. *Nature* 2022 1–10 (2022) doi:10.1038/s41586-022-04411-y.
- 926 38. Endo, A., Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in
927 COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Research*
928 *2020 5:67* 5, 67 (2020).
- 929 39. Wallinga, J. & Lipsitch, M. How generation intervals shape the relationship between
930 growth rates and reproductive numbers. *Proceedings of the Royal Society B:*
931 *Biological Sciences* **274**, 599–604 (2006).
- 932 40. Brümmer, L. E. *et al.* Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A
933 living systematic review and meta-analysis. *PLoS Med* **18**, e1003735- (2021).
- 934 41. Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-
935 2 viral kinetics and infection rebound: A retrospective cohort study. *Elife* **11**, (2022).
- 936 42. Boyton, R. J. & Altmann, D. M. The immunology of asymptomatic SARS-CoV-2
937 infection: what are the key questions? *Nature Reviews Immunology* 2021 21:12 **21**,
938 762–768 (2021).
- 939 43. Quilty, B. J. *et al.* Quarantine and testing strategies in contact tracing for SARS-CoV-
940 2: a modelling study. *Lancet Public Health* **6**, e175–e183 (2021).
- 941 44. National Institute For Public Health and The Environment (RIVM). Figures on the
942 COVID-19 vaccination programme. [https://www.rivm.nl/en/covid-19-](https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme)
943 [vaccination/figures-vaccination-programme](https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme) (2022).
- 944 45. Ritchie, H. *et al.* Coronavirus Pandemic (COVID-19). *Our World in Data* (2020).
- 945 46. National Institute for Public Health and the Environment (RIVM). COVID-19 dataset.
946 <https://data.rivm.nl/covid-19/> (2022).


- 947 47. World Health Organization. Therapeutics and COVID-19: living guideline.
948 <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.3>
949 (2022).
- 950 48. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.
951 *Nature* 2020 581:7809 **581**, 465–469 (2020).
952









a





b



a) Vaccination coverage = 10%**b) Vaccination coverage = 50%****c) Vaccination coverage = 90%**

a) Vaccination coverage = 10%**b) Vaccination coverage = 50%****c) Vaccination coverage = 90%**

a) Total infections**b) Severe cases****c) Deaths**